{"id":3222,"date":"2013-07-04T14:30:00","date_gmt":"2013-07-04T14:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/teckningsoptionsprogrammet-fulltecknat-4\/"},"modified":"2013-07-04T14:30:00","modified_gmt":"2013-07-04T14:30:00","slug":"teckningsoptionsprogrammet-fulltecknat-4","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/","title":{"rendered":"Teckningsoptionsprogrammet fulltecknat"},"content":{"rendered":"<p><span>XVIVO Perfusion ABs teckningsoptionsprogram 2013\/2015 \u00e4r fulltecknat. Totalt emitterades 195.000 optionsr\u00e4tter med \u00e5tf\u00f6ljande r\u00e4tt till nyteckning av aktier. Varje optionsr\u00e4tt har i juni 2015 r\u00e4tten att teckna en ny aktie till en kurs av 32,40 kronor. <\/span><\/p>\n<p><span>Aktie\u00e4garst\u00e4mman den 7 maj 2013 godk\u00e4nde teckningsoptionsprogrammet p\u00e5 maximalt 195.000 optionsr\u00e4tter f\u00f6r att erbjudas till samtliga anst\u00e4llda i XVIVO Perfusion AB. Vid fullt utnyttjande av optionsr\u00e4tterna kommer aktiekapitalet \u00f6ka med 5.070 kronor motsvarande en utsp\u00e4dning om cirka 1 procent av det totala antalet aktier och r\u00f6ster.<\/p>\n<p>Magnus Nilsson, XVIVO Perfusions VD: \u201d Den h\u00f6ga uppslutningen \u00e4r mycket gl\u00e4djande och g\u00f6r att alla v\u00e5ra anst\u00e4llda f\u00e5r ett starkare \u00e4garintresse och en \u00e4nnu starkare drivkraft att uppfylla v\u00e5ra m\u00e5l.\u201d<\/span><\/p>\n<p><span>G\u00f6teborg 4 juli 2013<br \/><\/span><span>XVIVO Perfusion AB (publ)<br \/><\/span><span>Magnus Nilsson<br \/><\/span><span>Verkst\u00e4llande direkt\u00f6r<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om Xvivo Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>Xvivo Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a04 juli 2013 kl. 16:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>XVIVO Perfusion ABs teckningsoptionsprogram 2013\/2015 \u00e4r fulltecknat. Totalt emitterades 195.000 optionsr\u00e4tter med \u00e5tf\u00f6ljande r\u00e4tt till nyteckning av aktier. Varje optionsr\u00e4tt&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3222","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Teckningsoptionsprogrammet fulltecknat - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teckningsoptionsprogrammet fulltecknat - XVIVO\" \/>\n<meta property=\"og:description\" content=\"XVIVO Perfusion ABs teckningsoptionsprogram 2013\/2015 \u00e4r fulltecknat. Totalt emitterades 195.000 optionsr\u00e4tter med \u00e5tf\u00f6ljande r\u00e4tt till nyteckning av aktier. Varje optionsr\u00e4tt...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/teckningsoptionsprogrammet-fulltecknat-4\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/teckningsoptionsprogrammet-fulltecknat-4\\\/\",\"name\":\"Teckningsoptionsprogrammet fulltecknat - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-07-04T14:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/teckningsoptionsprogrammet-fulltecknat-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/teckningsoptionsprogrammet-fulltecknat-4\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/teckningsoptionsprogrammet-fulltecknat-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teckningsoptionsprogrammet fulltecknat\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teckningsoptionsprogrammet fulltecknat - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/","og_locale":"en_US","og_type":"article","og_title":"Teckningsoptionsprogrammet fulltecknat - XVIVO","og_description":"XVIVO Perfusion ABs teckningsoptionsprogram 2013\/2015 \u00e4r fulltecknat. Totalt emitterades 195.000 optionsr\u00e4tter med \u00e5tf\u00f6ljande r\u00e4tt till nyteckning av aktier. Varje optionsr\u00e4tt...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/","name":"Teckningsoptionsprogrammet fulltecknat - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-07-04T14:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/teckningsoptionsprogrammet-fulltecknat-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Teckningsoptionsprogrammet fulltecknat"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}